secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001641172-25-017046
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA reports SKNY-1 achieves 30% weight loss and reverses cravings in zebrafish obesity model
--------------------------------------------------------------------------------

- SKNY-1 reduced body weight by ~30% in six days; treated animals weighed ~10% less than healthy controls.
- Liver fat buildup reversed to healthy levels; cholesterol (LDL/HDL) normalized without disrupting metabolic balance.
- Obese animals ate 2-3x more high-calorie food; SKNY-1 dose-dependently reduced compulsive eating and food-seeking.
- Nicotine craving and seeking behavior significantly reduced; high-dose group matched healthy animal behavior.
- Leptin and ghrelin normalized; lower-dose SKNY-1 reduced elevated brain dopamine linked to reward cravings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225017046/0001641172-25-017046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225017046/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer